Literature DB >> 31983229

Immunoproteasome-selective inhibitors: the future of autoimmune diseases?

Chong Zhang1, Huajian Zhu1, Jiaan Shao1, Ruoyu He2, Jianjun Xi2, Rangxiao Zhuang2, Jiankang Zhang1.   

Abstract

Entities:  

Keywords:  autoimmune diseases; design; immunoproteasome; selective inhibitor

Mesh：

Substances：

Year:  2020        PMID： 31983229     DOI： 10.4155/fmc-2019-0299

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  4 in total

Review 1.  Deubiquitylating enzymes: potential target in autoimmune diseases.

Authors:  Niraj Parihar; Lokesh Kumar Bhatt
Journal:  Inflammopharmacology       Date:  2021-11-18       Impact factor: 4.473

2.  Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors.

Authors:  Andrej Besse; Marianne Kraus; Max Mendez-Lopez; Elmer Maurits; Herman S Overkleeft; Christoph Driessen; Lenka Besse
Journal:  Cells       Date:  2022-03-01       Impact factor: 6.600

Review 3.  Immunoproteasome in IgA Nephropathy: State-of-Art and Future Perspectives.

Authors:  Ting Gan; Yang Li; Xu-Jie Zhou; Hong Zhang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

Review 4.  Immunoproteasome Function in Normal and Malignant Hematopoiesis.

Authors:  Nuria Tubío-Santamaría; Frédéric Ebstein; Florian H Heidel; Elke Krüger
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.